DK1548032T3 - KDR-peptider og vacciner indeholdende disse - Google Patents
KDR-peptider og vacciner indeholdende disseInfo
- Publication number
- DK1548032T3 DK1548032T3 DK03795432T DK03795432T DK1548032T3 DK 1548032 T3 DK1548032 T3 DK 1548032T3 DK 03795432 T DK03795432 T DK 03795432T DK 03795432 T DK03795432 T DK 03795432T DK 1548032 T3 DK1548032 T3 DK 1548032T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptides
- amino acid
- vaccines containing
- seq
- acid sequence
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464409—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002267285 | 2002-09-12 | ||
| JP2003062003 | 2003-03-07 | ||
| JP2003167042 | 2003-06-11 | ||
| PCT/JP2003/011722 WO2004024766A1 (ja) | 2002-09-12 | 2003-09-12 | Kdrペプチド及びこれを含むワクチン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1548032T3 true DK1548032T3 (da) | 2009-08-17 |
Family
ID=31998762
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10010169.0T DK2267021T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
| DK08018875.8T DK2014678T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner indeholdende disse |
| DK03795432T DK1548032T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner indeholdende disse |
| DK10010175.7T DK2267023T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
| DK10010174.0T DK2267022T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
| DK10010173.2T DK2261249T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10010169.0T DK2267021T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
| DK08018875.8T DK2014678T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner indeholdende disse |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10010175.7T DK2267023T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
| DK10010174.0T DK2267022T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
| DK10010173.2T DK2261249T3 (da) | 2002-09-12 | 2003-09-12 | KDR-peptider og vacciner omfattende det samme |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7514084B2 (da) |
| EP (11) | EP2014679B1 (da) |
| JP (3) | JP3971769B2 (da) |
| CN (5) | CN103951745A (da) |
| AT (2) | ATE432291T1 (da) |
| AU (1) | AU2003264419A1 (da) |
| CY (2) | CY1109463T1 (da) |
| DE (1) | DE60327786D1 (da) |
| DK (6) | DK2267021T3 (da) |
| ES (2) | ES2327040T3 (da) |
| HK (7) | HK1124077A1 (da) |
| PT (2) | PT2014678E (da) |
| SI (2) | SI1548032T1 (da) |
| WO (1) | WO2004024766A1 (da) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024766A1 (ja) | 2002-09-12 | 2004-03-25 | Oncotherapy Science, Inc. | Kdrペプチド及びこれを含むワクチン |
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| DK2325305T3 (da) * | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptidvacciner til lungecancere, der udtrykker TTK-, URLC10- eller KOC1-polypeptid |
| ES2385396T3 (es) * | 2005-02-28 | 2012-07-24 | Oncotherapy Science, Inc. | Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos |
| US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| US7943295B2 (en) | 2005-07-29 | 2011-05-17 | Oncotherapy Science, Inc. | Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex |
| PT2347775T (pt) | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
| ES2657480T3 (es) * | 2006-08-11 | 2018-03-05 | Life Sciences Research Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| TWI441648B (zh) * | 2007-01-03 | 2014-06-21 | Oncotherapy Science Inc | Ｆｏｘｐ３胜肽疫苗 |
| KR101493775B1 (ko) | 2007-02-16 | 2015-02-16 | 온코세라피 사이언스 가부시키가이샤 | 맥락막 신생혈관용 백신 치료 |
| TW201425333A (zh) * | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| JP5493076B2 (ja) * | 2007-08-20 | 2014-05-14 | オンコセラピー・サイエンス株式会社 | Ｃｄｃａ１ペプチド及びこれを含む薬剤 |
| AU2008290049B2 (en) | 2007-08-20 | 2013-08-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
| TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| TW200932260A (en) * | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
| CA2715460C (en) | 2008-02-13 | 2020-02-18 | President And Fellows Of Harvard College | Continuous cell programming devices |
| CA2715611C (en) | 2008-02-14 | 2018-03-13 | Life Sciences Research Partners Vzw | Immunotherapy targeting intracellular pathogens |
| ES2650236T3 (es) | 2008-02-14 | 2018-01-17 | Life Sciences Research Partners Vzw | Linfocitos T CD4+ con propiedades citolíticas |
| ES2545885T3 (es) | 2008-02-14 | 2015-09-16 | Life Sciences Research Partners Vzw | Eliminación de respuestas inmunitarias contra vectores virales |
| AU2009214039B2 (en) | 2008-02-14 | 2013-09-19 | Katholieke Universiteit Leuven | Immunogenic control of tumours and tumour cells |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| TWI526219B (zh) * | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| RU2532105C2 (ru) | 2008-10-22 | 2014-10-27 | Онкотерапи Сайенс, Инк. | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины |
| TWI539160B (zh) * | 2008-12-05 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| TW201032820A (en) * | 2008-12-16 | 2010-09-16 | Oncotherapy Science Inc | ELOVL7 epitope peptides and vaccines containing the same |
| BRPI0923402A2 (pt) * | 2008-12-24 | 2015-08-04 | Oncotherapy Science Inc | Peptídeos c10rf59 e vacinas incluindo os mesmos. |
| JP6053255B2 (ja) | 2009-01-08 | 2016-12-27 | 株式会社癌免疫研究所 | 新規癌抗原ｅＥＦ２ |
| JP2012519470A (ja) * | 2009-03-04 | 2012-08-30 | オンコセラピー・サイエンス株式会社 | Ｖａｎｇｌ１ペプチドおよびそれを含むワクチン |
| JP5799394B2 (ja) | 2009-03-18 | 2015-10-28 | オンコセラピー・サイエンス株式会社 | Ｎｅｉｌ３ペプチドおよびそれを含むワクチン |
| TW201100090A (en) * | 2009-04-01 | 2011-01-01 | Oncotherapy Science Inc | C6orf167 peptides and vaccines containing the same |
| TWI507204B (zh) | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗 |
| TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
| AU2010278702C1 (en) | 2009-07-31 | 2016-07-14 | Forsyth Dental Infirmary For Children | Programming of cells for tolerogenic therapies |
| TW201200525A (en) * | 2009-12-04 | 2012-01-01 | Oncotherapy Science Inc | MYBL2 peptides and vaccines containing the same |
| TW201136604A (en) | 2009-12-14 | 2011-11-01 | Oncotherapy Science Inc | TMEM22 peptides and vaccines including the same |
| CN102115492B (zh) * | 2010-01-05 | 2013-03-06 | 中国农业科学院北京畜牧兽医研究所 | 血管内皮生长因子受体部分多肽及其应用 |
| SG10201501857YA (en) * | 2010-03-11 | 2015-05-28 | Oncotherapy Science Inc | Hjurp Peptides And Vaccines Including The Same |
| TW201134480A (en) * | 2010-04-08 | 2011-10-16 | Oncotherapy Science Inc | CLUAP1 peptides and vaccines including the same |
| KR20130043627A (ko) * | 2010-04-09 | 2013-04-30 | 온코세라피 사이언스 가부시키가이샤 | Cdca5 펩티드 및 이를 포함한 백신 |
| WO2012032763A1 (en) * | 2010-09-07 | 2012-03-15 | Oncotherapy Science, Inc. | Vangl1 peptides and vaccines including the same |
| US11202759B2 (en) | 2010-10-06 | 2021-12-21 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
| PT2643345T (pt) | 2010-11-25 | 2021-04-14 | Imnate Sarl | Péptidos imunogénicos para utilizar na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunitárias a alofatores, doenças alérgicas, tumores, rejeição de enxertos e respostas imunitárias contra vetores virais usados para a terapêutica de genes ou na vacinação genética |
| UA110119C2 (xx) * | 2010-12-02 | 2015-11-25 | Пептиди tomm34 та вакцини, що їх містять | |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
| SI2838515T1 (sl) | 2012-04-16 | 2020-07-31 | President And Fellows Of Harvard College | Mezoporozni sestavki iz silicijevega dioksida za moduliranje imunskih odgovorov |
| CN104470950B (zh) | 2012-05-11 | 2017-04-26 | 公益财团法人微生物化学研究会 | 抗cxadr抗体 |
| JP6255593B2 (ja) | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン |
| CA2892369A1 (en) * | 2012-12-04 | 2014-06-12 | Oncotherapy Science, Inc. | Sema5b peptides and vaccines containing the same |
| US9932396B2 (en) | 2013-02-08 | 2018-04-03 | Medical & Biological Laboratories Co., Ltd. | Antibody against human NRG1 protein |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| JP2017042047A (ja) * | 2013-12-06 | 2017-03-02 | オンコセラピー・サイエンス株式会社 | Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン |
| US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| WO2016129335A1 (ja) * | 2015-02-09 | 2016-08-18 | 株式会社ライフアートビレッジ | 免疫細胞療法のためのペプチドスクリーニング方法 |
| WO2016164705A1 (en) | 2015-04-10 | 2016-10-13 | Omar Abdel-Rahman Ali | Immune cell trapping devices and methods for making and using the same |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| CA2995771A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| CN105200010B (zh) * | 2015-10-15 | 2019-02-12 | 首都医科大学附属北京佑安医院 | 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基 |
| CN109072197A (zh) | 2016-02-06 | 2018-12-21 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
| KR20220132023A (ko) | 2016-04-19 | 2022-09-29 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
| US11555177B2 (en) | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| CN110612115A (zh) * | 2017-05-19 | 2019-12-24 | 学校法人庆应义塾 | 针对脑神经疾病的肽疫苗和肽疫苗组合物 |
| CN111363026B (zh) * | 2020-03-31 | 2022-03-25 | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 一种增强抗原多肽亲和力和稳定性的方法 |
| KR102711471B1 (ko) * | 2020-08-14 | 2024-09-30 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861301A (en) * | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| US6222012B1 (en) * | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
| CN1701814A (zh) * | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k－1 |
| ATE281469T1 (de) * | 1993-03-25 | 2004-11-15 | Merck & Co Inc | Inhibitor des wachstumsfaktors für gefäss- endothelzellen |
| AU6632496A (en) * | 1995-08-03 | 1997-03-05 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6080728A (en) * | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| US5942428A (en) * | 1996-08-21 | 1999-08-24 | Sugen, Inc. | Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| US6348333B1 (en) * | 1997-01-17 | 2002-02-19 | Toa Gosei Co., Ltd. | VEGF-binding KDR polypeptide |
| ATE371727T1 (de) * | 1997-06-18 | 2007-09-15 | Merck & Co Inc | Kdr, ein menschlicher tyrosin kinase rezeptor |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| NZ504938A (en) * | 1997-12-05 | 2002-10-25 | Kyogo Itoh | Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen |
| AU2299099A (en) * | 1998-02-04 | 1999-08-23 | Kyowa Hakko Kogyo Co. Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) * | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| CA2328893A1 (en) | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
| NZ508996A (en) | 1998-06-25 | 2003-09-26 | Kyogo Itoh | Tumor antigen peptides derived from cyclophilin B |
| WO2001012809A2 (en) * | 1999-08-13 | 2001-02-22 | Crucell Holland B.V. | Heterodimeric vegf variants used for inhibiting angiogenesis |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| JP2002267285A (ja) | 2001-03-12 | 2002-09-18 | Denso Corp | 冷房冷蔵装置 |
| JP4068371B2 (ja) | 2001-06-13 | 2008-03-26 | 株式会社トプコン | 手術用顕微鏡 |
| JP3640084B2 (ja) | 2001-11-30 | 2005-04-20 | 日本電気株式会社 | 測位機能を搭載した携帯電話端末 |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| WO2004024766A1 (ja) * | 2002-09-12 | 2004-03-25 | Oncotherapy Science, Inc. | Kdrペプチド及びこれを含むワクチン |
| AU2003272471B2 (en) | 2002-09-18 | 2010-10-07 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| ES2385396T3 (es) | 2005-02-28 | 2012-07-24 | Oncotherapy Science, Inc. | Péptidos epítopos derivados del receptor 1 del factor de crecimiento endotelial vascular y vacunas que contienen estos péptidos |
| KR101493775B1 (ko) | 2007-02-16 | 2015-02-16 | 온코세라피 사이언스 가부시키가이샤 | 맥락막 신생혈관용 백신 치료 |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
-
2003
- 2003-09-12 WO PCT/JP2003/011722 patent/WO2004024766A1/ja active Application Filing
- 2003-09-12 DE DE60327786T patent/DE60327786D1/de not_active Expired - Lifetime
- 2003-09-12 ES ES03795432T patent/ES2327040T3/es not_active Expired - Lifetime
- 2003-09-12 SI SI200331649T patent/SI1548032T1/sl unknown
- 2003-09-12 PT PT08018875T patent/PT2014678E/pt unknown
- 2003-09-12 SI SI200332101T patent/SI2014678T1/sl unknown
- 2003-09-12 DK DK10010169.0T patent/DK2267021T3/da active
- 2003-09-12 EP EP08018897A patent/EP2014679B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN201410214247.3A patent/CN103951745A/zh active Pending
- 2003-09-12 AT AT03795432T patent/ATE432291T1/de active
- 2003-09-12 EP EP10010170.8A patent/EP2270041B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP08018875A patent/EP2014678B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010171A patent/EP2261247A3/en not_active Withdrawn
- 2003-09-12 EP EP10010169.0A patent/EP2267021B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010174.0A patent/EP2267022B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010176.5A patent/EP2270042B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN2007101802067A patent/CN101139393B/zh not_active Expired - Fee Related
- 2003-09-12 US US10/527,496 patent/US7514084B2/en not_active Expired - Fee Related
- 2003-09-12 DK DK08018875.8T patent/DK2014678T3/da active
- 2003-09-12 DK DK03795432T patent/DK1548032T3/da active
- 2003-09-12 EP EP10010175.7A patent/EP2267023B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN201210430723.6A patent/CN103073620B/zh not_active Expired - Fee Related
- 2003-09-12 ES ES08018875T patent/ES2375299T3/es not_active Expired - Lifetime
- 2003-09-12 AU AU2003264419A patent/AU2003264419A1/en not_active Abandoned
- 2003-09-12 EP EP03795432A patent/EP1548032B9/en not_active Expired - Lifetime
- 2003-09-12 CN CN2007101802052A patent/CN101139392B/zh not_active Expired - Fee Related
- 2003-09-12 DK DK10010175.7T patent/DK2267023T3/da active
- 2003-09-12 DK DK10010174.0T patent/DK2267022T3/da active
- 2003-09-12 EP EP10010172.4A patent/EP2261248B1/en not_active Expired - Lifetime
- 2003-09-12 CN CNB038250810A patent/CN100352843C/zh not_active Expired - Lifetime
- 2003-09-12 DK DK10010173.2T patent/DK2261249T3/da active
- 2003-09-12 PT PT03795432T patent/PT1548032E/pt unknown
- 2003-09-12 JP JP2004571938A patent/JP3971769B2/ja not_active Expired - Lifetime
- 2003-09-12 EP EP10010173.2A patent/EP2261249B1/en not_active Expired - Lifetime
- 2003-09-12 AT AT08018875T patent/ATE531729T1/de active
-
2007
- 2007-03-08 JP JP2007058127A patent/JP4185143B2/ja not_active Expired - Fee Related
- 2007-05-08 JP JP2007123850A patent/JP4185147B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-16 US US12/355,616 patent/US7695720B2/en not_active Expired - Lifetime
- 2009-04-30 HK HK09104058.2A patent/HK1124077A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK09104475.7A patent/HK1125659A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104995.4A patent/HK1151038A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104992.7A patent/HK1151036A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104996.3A patent/HK1151039A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104993.6A patent/HK1151037A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104977.6A patent/HK1151032A1/xx not_active IP Right Cessation
- 2009-08-12 CY CY20091100856T patent/CY1109463T1/el unknown
-
2010
- 2010-02-23 US US12/711,159 patent/US8206719B2/en not_active Expired - Fee Related
-
2012
- 2012-01-19 CY CY20121100072T patent/CY1113379T1/el unknown
- 2012-06-12 US US13/494,933 patent/US8574586B2/en not_active Expired - Fee Related
- 2012-06-12 US US13/494,930 patent/US8574585B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1548032T3 (da) | KDR-peptider og vacciner indeholdende disse | |
| WO2006090810A3 (en) | Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| BR0211199A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| DK2289533T3 (da) | Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider | |
| DE60230456D1 (de) | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren | |
| ATE495247T1 (de) | Chromoprotein und fluoroproteine | |
| DE69426121D1 (de) | Gen grb3-3, variante und ihre verwendungen | |
| DK1095143T3 (da) | Inhibitor til diagnosticering og behandling af patienter med hæmofili A | |
| EP2370454A4 (en) | PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM | |
| DK1673391T3 (da) | Modificeret cDNA til höje ekspressionsniveauer af faktor VIII og dens derivater | |
| WO2007026171A3 (en) | Vdcc gamma-8 ion channel | |
| DE10394174D2 (de) | Peptide mit hohem Cysteingehalt |